Anti-LIMA1/ EPLIN/ LDLCQ8 monoclonal antibody

Anti-LIMA1/ EPLIN/ LDLCQ8 antibody for FACS & in-vivo assay

Target products collectionGo to LIMA1/LIMA1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2185-Ab-1/ GM-Tg-hg-MP2185-Ab-2Anti-Human LIMA1 monoclonal antibodyHuman
GM-Tg-rg-MP2185-Ab-1/ GM-Tg-rg-MP2185-Ab-2Anti-Rat LIMA1 monoclonal antibodyRat
GM-Tg-mg-MP2185-Ab-1/ GM-Tg-mg-MP2185-Ab-2Anti-Mouse LIMA1 monoclonal antibodyMouse
GM-Tg-cynog-MP2185-Ab-1/ GM-Tg-cynog-MP2185-Ab-2Anti-Cynomolgus/ Rhesus macaque LIMA1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2185-Ab-1/ GM-Tg-felg-MP2185-Ab-2Anti-Feline LIMA1 monoclonal antibodyFeline
GM-Tg-cang-MP2185-Ab-1/ GM-Tg-cang-MP2185-Ab-2Anti-Canine LIMA1 monoclonal antibodyCanine
GM-Tg-bovg-MP2185-Ab-1/ GM-Tg-bovg-MP2185-Ab-2Anti-Bovine LIMA1 monoclonal antibodyBovine
GM-Tg-equg-MP2185-Ab-1/ GM-Tg-equg-MP2185-Ab-2Anti-Equine LIMA1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2185-Ab-1/ GM-Tg-hg-MP2185-Ab-2; GM-Tg-rg-MP2185-Ab-1/ GM-Tg-rg-MP2185-Ab-2;
GM-Tg-mg-MP2185-Ab-1/ GM-Tg-mg-MP2185-Ab-2; GM-Tg-cynog-MP2185-Ab-1/ GM-Tg-cynog-MP2185-Ab-2;
GM-Tg-felg-MP2185-Ab-1/ GM-Tg-felg-MP2185-Ab-2; GM-Tg-cang-MP2185-Ab-1/ GM-Tg-cang-MP2185-Ab-2;
GM-Tg-bovg-MP2185-Ab-1/ GM-Tg-bovg-MP2185-Ab-2; GM-Tg-equg-MP2185-Ab-1/ GM-Tg-equg-MP2185-Ab-2
Products NameAnti-LIMA1 monoclonal antibody
Formatmab
Target NameLIMA1
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LIMA1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species LIMA1/ EPLIN/ LDLCQ8 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2185
    Target NameLIMA1
    Gene ID51474,65970,300228,713519,477610,101087494,540637,100060033
    Gene Symbol and SynonymsEPLIN,LDLCQ8,LIMA1,SREBP3
    Uniprot AccessionQ9UHB6,F1LR10
    Uniprot Entry NameLIMA1_HUMAN,LIMA1_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000050405
    Target ClassificationN/A

    The target: LIMA1, gene name: LIMA1, also named as EPLIN, LDLCQ8, SREBP3. This gene encodes a cytoskeleton-associated protein that inhibits actin filament depolymerization and cross-links filaments in bundles. It is downregulated in some cancer cell lines. Alternatively spliced transcript variants encoding different isoforms have been described for this gene, and expression of some of the variants maybe independently regulated. [provided by RefSeq, Aug 2011].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.